Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Regeneron shares poised for rebound: Barron's

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2017 | 07:19pm CEST

(Reuters) - Shares of Regeneron Pharmaceuticals Inc, which tumbled 32 percent in 2016, are poised for a rebound, the financial newspaper Barron's said.

A better-than-expected launch of Regeneron's skin treatment Dupixent caused shares to soar last week, the paper reported in its May 8 edition. If Dupixent usage grows faster than expected, it could take pressure off Regeneron's other drugs, including eye drug Eylea, Barron's said.

Regeneron said that 900 prescriptions had been written for Dupixent and that the number of doctors prescribing the drug had jumped by nearly 50 percent.

(Reporting by Olivia Oran; Editing by Phil Berlowitz)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
04/26REGENERON PHARMACEUTICALS : Patent Issued for Inducible Eukaryotic Expression Sy..
AQ
04/23REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
PR
04/12REGENERON PHARMACEUTICALS : EMA to Review Cemiplimab as a Potential Treatment fo..
AQ
04/12FINDINGS ON PSORIASIS REPORTED BY IN : A Systematic Review)
AQ
04/11DIABETIC RETINOPATHY DRUG MARKET PRO : Global Diabetic Retinopathy Drug Market B..
AQ
04/09REGENERON PHARMACEUTICALS : to Report First Quarter 2018 Financial and Operating..
PR
04/06SANOFI : - EMA to review cemiplimab as a potential treatment for advanced cutane..
AQ
04/05SANOFI : - EMA to review Dupixent as potential treatment for inadequately contro..
AQ
04/04REGENERON PHARMACEUTICALS : EMA to Review DUPIXENT (dupilumab) as Potential Trea..
AQ
03/29REGENERON PHARMACEUTICALS : and Alnylam Pharmaceuticals Announce Collaboration t..
AQ
More news
News from SeekingAlpha
04/26Amgen's Dim Sales Outlook Looms Over Buybacks 
04/23Unity Biotechnology Finalizes $85 Million IPO Terms 
04/23OAKMARK EQUITY AND INCOME FUND : Q1 2018 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
Financials ($)
Sales 2018 6 387 M
EBIT 2018 2 474 M
Net income 2018 1 709 M
Finance 2018 3 115 M
Yield 2018 -
P/E ratio 2018 21,76
P/E ratio 2019 18,59
EV / Sales 2018 4,77x
EV / Sales 2019 4,03x
Capitalization 33 601 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 418 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-17.01%33 601
GILEAD SCIENCES1.51%94 816
VERTEX PHARMACEUTICALS3.88%39 523
GENMAB18.71%12 384
BEIGENE LTD (ADR)69.87%9 095
BLUEBIRD BIO INC-8.70%8 147